Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 14/20 | 0.79 |
| ▸ | P2RY4 | P51582 | 9/20 | 0.79 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.76 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1620405 | 0.91 | P2RY2 (0.78) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL1620404 | 0.91 | P2RY2 (0.78) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL3502216 | 0.91 | P2RY2 (0.76) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL4575896 | 0.91 | P2RY2 (0.76) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL1996226 | 0.91 | P2RY2 (0.76) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL23705843 | 0.91 | P2RY2 (0.76) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL1230649 | 0.90 | P2RY2 (0.92) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL5960971 | 0.90 | P2RY2 (0.92) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL29239784 | 0.90 | P2RY2 (0.92) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL28484026 | 0.90 | P2RY2 (0.92) | P2RY2P2RY4P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193202-A1 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | ADISPELL, INC. | 2016-07-07 | — | — | US | disclosed |
| WO-2015023664-A2 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | ADISPELL, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| WO-2014011768-A1 | ANTI-ANXIETY TREATMENT | ADISPELL, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2012177856-A2 | COGNITION MODIFICATION | ADISPELL, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2008125116-A2 | UPAR INHIBITION | AARHUS UNIVERSITET (DK) | 2008-10-23 | — | — | WO | disclosed |
| EP-1793006-A2 | Nucleic acid ligands and improved methods for producing the same | GILEAD SCIENCES, INC. (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1654362-A2 | 5'-AND 3'-CAPPED APTAMERS AND USES THEREFOR | EYETECH PHARMACEUTICALS, INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20060036087-A1 | 2'-deoxy-2'-fluoro modified RNA | RIBOZYME PHARMACEUTICALS, INC. | 2006-02-16 | — | — | US | disclosed |
| US-6890908-B1 | Modified ribozymes | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-05-10 | — | — | US | disclosed |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | (OSI) EYETECH, INC. | 2005-05-05 | — | — | US | disclosed |
| US-5958691-A | DETECTION OF NUCLEIC ACID LIGANDS WITH MODIFIED NUCLEOTIDE TO TARGET GROUPS, SINGLE STRAND NUCLEIC ACIDS AND PARTITIONING THE NUCLEIC ACIDS, AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5817635-A | RNA MOLECULES WITH CATALYTIC ACTIVITY | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1998-10-06 | — | — | US | disclosed |
| US-5698687-A | RNA MOLECULE CONTAINING MODIFIED NUCLOSIDE | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1997-12-16 | — | — | US | disclosed |
| US-5672695-A | GENETIC ENGINEERED RNA MOLECULE, ATLEAST ONE MODIFIED NUCLEOSIDE HAVING A HALO, AMINO, MONO OR DISUBSTITUTED AMINO AND AZIDE MODIFIER GROUPS REPLACING HYDROXY GROUP AT 2' POSITION OF DRIBOSE SUGAR; SHOWS CATALYTIC ACTIVITY | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1997-09-30 | — | — | US | disclosed |
| US-5660985-A | CONTACTING MIXTURE OF MODIFIED SINGLE-STRANDED NUCLEIC ACIDS WITH TARGET MOLECULE, PARTITIONING THOSE WITH INCREASED AFFINITY, AMPLIFYING TO IDENTIFY LIGANDS OF TARGET MOLECULE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-08-26 | — | — | US | disclosed |
| EP-0552178-B1 | MODIFIED RIBOZYMES | MAX PLANCK GESELLSCHAFT (DE) | 1997-01-02 | — | — | EP | disclosed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | disclosed |
| EP-0552178-A1 | MODIFIED RIBOZYMES. | MAX PLANCK GESELLSCHAFT (DE) | 1993-07-28 | — | — | EP | disclosed |
| WO-1992007065-A1 | MODIFIED RIBOZYMES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193202-A1 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | CHRNG, CHRM3, CHRNA5 | P2RY2 1153/4885P2RY4 1481/4885P2RY6 1137/4885 |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | FLT4, TEK, FLT1 | P2RY2 1820/4885P2RY4 984/4885P2RY6 1295/4885 |
| US-20060036087-A1 | 2'-deoxy-2'-fluoro modified RNA | RNGTT, NSUN2, NSUN3 | P2RY2 2102/4885P2RY4 2866/4885P2RY6 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.